


**Patent Claims****1. Compounds of formula I****(I)**

in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

- 79 -

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,

or

T2 is 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, 4N-(1-4C-alkyl)-piperazino, imidazolo, pyrrolo or pyrazolo,

R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,


Aa1 is a bisaryl radical made up of two aryl groups, which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond,

Hh1 is a bisheteroaryl radical made up of two heteroaryl groups, which are selected independently from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond,

Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond,

- 80 -

R7 is hydroxyl, or Cyc1, in which  
Cyc1 is a ring system of formula Ia



in which

A is C (carbon),

B is C (carbon),

R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,

M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which

Ar2 is a benzene ring,

Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,

and the salts of these compounds.

## 2. Compounds of formula I according to claim 1

in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which


T2 is a bond, 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen,

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

- 81 -

- R6111 is halogen, or 1-4C-alkyl,  
 R6112 is 1-4C-alkyl,  
 R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,  
 R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,
- Aa1 is a bisaryl radical made up of two aryl groups,  
 which are selected independently from a group consisting of phenyl and naphthyl, and  
 which are linked together via a single bond,
- Hh1 is a bisheteroaryl radical made up of two heteroaryl groups,  
 which are selected independently from a group consisting of monocyclic 5- or 6-membered  
 heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the  
 group consisting of nitrogen, oxygen and sulfur, and  
 which are linked together via a single bond,
- Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected  
 from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or  
 two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and  
 sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said  
 heteroaryl and aryl groups are linked together via a single bond,
- R7 is hydroxyl, or Cyc1, in which  
 Cyc1 is a ring system of formula Ia



in which

- A is C (carbon),  
 B is C (carbon),  
 R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
 R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
 M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which  
 Ar2 is a benzene ring,

- 82 -

Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,  
and the salts of these compounds.

3. Compounds of formula I according to claim 1

in which

R1 is hydrogen, or 1-4C-alkyl,

R2 is hydrogen, or 1-4C-alkyl,

R3 is hydrogen, or 1-4C-alkyl,

R4 is hydrogen, or 1-4C-alkyl,

R5 is hydrogen, or 1-4C-alkyl,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is either

a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or

a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or

a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

or

T2 is 1-4C-alkylene,

- 83 -

- R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which  
 Har1 is either  
 a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or  
 a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is a biphenyl radical,  
 Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-pyridinyl, or pyridinyl-thiophenyl radical,  
 Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or imidazolyl-phenyl radical,  
 R7 is hydroxyl, or 2-aminophenyl,  
 and the salts of these compounds.

#### 4. Compounds of formula I according to claim 1

in which

- R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, or Ah1, in which  
 T1 is a bond, or 1-2C-alkylene,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which

- 84 -

Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 or  
 T2 is 1-2C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is a biphenyl radical,  
 Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-pyridinyl, or pyridinyl-thiophenyl radical,  
 Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or imidazolyl-phenyl radical,  
 R7 is hydroxyl, or 2-aminophenyl,  
 and the salts of these compounds.

##### 5. Compounds of formula I according to claim 1

in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is 1-4C-alkyl, and  
 R612 is 1-4C-alkyl,  
 or  
 T2 is 1-2C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which

- 85 -

Har1 is pyridinyl, or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is a pyridinyl-thiophenyl radical,  
 Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl radical,  
 R7 is hydroxyl, or 2-aminophenyl,  
 and the salts of these compounds.

## 6. Compounds of formula I according to claim 1

in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either

T2 is a bond,  
 R611 is methyl, and  
 R612 is methyl,

or

T2 is methylene,  
 R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
 Har1 is pyridinyl or indolyl, and  
 R612 is hydrogen, methyl, or 2-hydroxy-ethyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which

Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is a pyridinyl-thiophenyl radical,  
 Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl radical,



- 86 -

R7 is hydroxyl, or 2-aminophenyl,  
and the salts of these compounds.

7. Compounds of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which  
Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,  
R611 is methyl, and  
R612 is methyl,

or

T2 is methylene,  
R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and  
R612 is hydrogen, methyl, or 2-hydroxy-ethyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which

Het1 is morpholino,  
Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,  
Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,  
R7 is hydroxyl, or 2-aminophenyl,  
and the salts of these compounds.

8. Compounds of formula I according to claim 1  
in which

R1 is hydrogen,

- 87 -

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which

R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is methyl, and

R612 is methyl,

or

T2 is methylene,

R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which

Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and

R612 is hydrogen,

or

T2 is methylene,

R611 is methyl, or 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is methyl,

or

T2 is methylene,

R611 is 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is 2-hydroxy-ethyl,

or

T2 is methylene, and

R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,

Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,

Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,

- 88 -

R7 is hydroxyl,  
and the salts of these compounds.

**9.** Compounds of formula I according to claim 1

in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which

T1 is a bond,

Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which

R61 is methyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is methyl, and

R612 is methyl,

or

T2 is methylene,

R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which

Har1 is pyridin-3-yl, pyridin-4-yl, indol-3-yl, or indol-5-yl, and

R612 is hydrogen,

or

T2 is methylene,

R611 is methyl, or 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is methyl,

or

T2 is methylene,

R611 is 2-(Har1)-ethyl, in which

Har1 is indol-2-yl, and

R612 is 2-hydroxy-ethyl,

or

T2 is methylene, and

R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

- 89 -

Het1 is morpholino,  
Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,  
Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-pyrazol-4-yl)-phenyl,  
R7 is 2-aminophenyl,  
and the salts of these compounds.

**10.** Compounds of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, or biphenyl, in which  
T1 is a bond, or 1-2C-alkylene,  
Q1 is Ar1, in which  
Ar1 is phenyl, or R61-substituted phenyl, in which  
R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
T2 is a bond, or 1-2C-alkylene,  
R611 is 1-4C-alkyl, or Har1-1-2C-alkyl, in which  
Har1 is benzimidazolyl, or indolyl,  
R612 is 1-4C-alkyl,  
R7 is hydroxyl, or 2-aminophenyl,  
and the salts of these compounds.

**11.** Compounds of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, biphenyl, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which

- 90 -

Ar1 is R61-substituted phenyl, in which  
 R61 is methyl, dimethylamino, or -T2-N(R611)R612, in which  
 T2 is methylene,  
 R611 is methyl, or 2-(indol-2-yl)ethyl,  
 R612 is methyl,  
 R7 is hydroxyl, or 2-aminophenyl,  
 and the salts of these compounds.

**12.** A compound of formula I according to claim 1 which is selected from

1. (E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
2. N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide
3. (E)-3-[1-(Biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
4. (E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
5. (E)-N-(2-Amino-phenyl)-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
6. (E)-N-(2-Amino-phenyl)-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide
7. (E)-N-(2-Amino-phenyl)-3-[1-(biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
8. (E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
9. (E)-N-Hydroxy-3-(1-[4-((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl]-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide
10. (E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
11. (E)-N-Hydroxy-3-[1-(4-[(pyridin-3-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
12. (E)-N-Hydroxy-3-[1-(4-[(1H-indol-3-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
13. (E)-3-[1-(4-(Benzylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
14. (E)-N-Hydroxy-3-[1-(4-(isobutylamino-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
15. (E)-N-Hydroxy-3-[1-(4-[(1H-indol-5-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
16. (E)-N-Hydroxy-3-[1-(4-[(pyridin-4-ylmethyl)-amino]-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
17. (E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
18. (E)-N-Hydroxy-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
19. (E)-N-Hydroxy-3-[1-(4-(1H-pyrazol-4-yl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
20. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
21. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
22. (E)-N-(2-Amino-phenyl)-3-[1-(4-(1H-pyrazol-4-yl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
23. (E)-3-[1-(Biphenyl-3-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
24. (E)-N-Hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide

- 91 -

25. (E)-N-Hydroxy-3-[1-(4-pyrazol-1-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
26. (E)-N-(2-Amino-phenyl)-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
27. (E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
28. (E)-N-Hydroxy-3-{1-[4-({(2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino}-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide
29. (E)-N-Hydroxy-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
30. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
31. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
32. (E)-N-Hydroxy-3-{1-[3-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide and
33. (E)-N-(2-Amino-phenyl)-3-{1-[3-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide, or a salt thereof.

**13.** Compounds of formula I as claimed in claim 1 for use in the treatment of diseases.

**14.** A pharmaceutical composition comprising on or more compounds of formula I as claimed in claim 1 together with customary pharmaceutical excipients and/or vehicles.

**15.** Use of compounds of formula I as claimed in claim 1 for the manufacture of pharmaceutical compositions for treating diseases responsive or sensitive to inhibition of histone deacetylase activity.

**16.** Use of compounds of formula I as claimed in claim 1 for the manufacture of pharmaceutical compositions for treating benign and/or malignant neoplasia, such as e.g. cancer.

**17.** Use of compounds of formula I as claimed in claim 1 for the manufacture of pharmaceutical compositions for treating diseases different to malignant neoplasia, such as e.g. arthropathies and osteopathological conditions, systemic lupus erythematosus, rheumatoid arthritis, smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, or inflammatory conditions.

**18.** A method for treating diseases in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1.

**19.** A method for treating benign and/or malignant neoplasia, such as e.g. cancer, in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, optionally, simultaneously, sequentially or separately with one or more further therapeutic agents.

- 92 -

20. A method for treating non-malignant diseases, such as e.g. arthropathies and osteopathological conditions, systemic lupus erythematosus, rheumatoid arthritis, smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, or inflammatory conditions, in a patient comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1, optionally, simultaneously, sequentially or separately with one or more further therapeutic agents.